l e t t e r s Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Here, we performed high-resolution copy-number analysis on 125 HCC tumors and wholeexome sequencing on 24 of these tumors. We identified 135 homozygous deletions and 994 somatic mutations of genes with predicted functional consequences. We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC. Functional analyses showed tumor suppressor properties for IRF2, whose inactivation, exclusively found in hepatitis B virus (HBV)-related tumors, led to impaired TP53 function. In contrast, inactivation of chromatin remodelers was frequent and predominant in alcohol-related tumors. Moreover, association of mutations in specific genes (RPS6KA3-AXIN1 and NFE2L2-CTNNB1) suggested that Wnt/b-catenin signaling might cooperate in liver carcinogenesis with both oxidative stress metabolism and Ras/mitogen-activated protein kinase (MAPK) pathways. This study provides insight into the somatic mutational landscape in HCC and identifies interactions between mutations in oncogene and tumor suppressor gene mutations related to specific risk factors.
Hepatocellular carcinoma is the third most frequent cause of cancerrelated mortality worldwide and is usually associated with specific risk factors, including hepatitis B or C infection, high alcohol intake, hemochromatosis or nonalcoholic fatty liver disease (NAFLD) caused by obesity and insulin resistance 1, 2 . More than 90% of HCC cases arise in the context of chronic hepatitis and cirrhosis, and this cancer is increasingly becoming a health problem. Here, we analyzed the whole-exome sequences of 24 human HCC tumors and paired nontumor liver tissues, with many of these tumors occurring in individuals with high alcohol intake (Online Methods and Supplementary  Tables 1 and 2 ). In total, we analyzed 125 HCC tumors related to various risk factors to identify chromosomal alterations and validate the recurrently mutated genes found by exome sequencing (Supplementary Tables 1 and 2 ).
For the 24 pairs of tumors and matched normal liver, we obtained 73-fold mean sequence coverage of targeted exonic regions, with 76% of loci covered at >25-fold (Supplementary Fig. 1 ). To search for somatic mutations, we identified nucleotide variants that were present in all tumors and absent in corresponding non-tumor tissue, by filtering the data according to an experimental flowchart that was applied to all the samples (Supplementary Fig. 2 ).Then, we selected the mutations that were highly predicted to impair the function of the corresponding encoded proteins. We identified 994 mutations that were further verified by Sanger sequencing to represent somatic events altering 906 different genes (Supplementary Table 3 ). The number of somatic mutations with predicted functional consequences per tumor was highly variable, ranging from 5 to 121 events (Fig. 1a) . As is typical in solid tumors 3 , most of the variants (74%) led to missense changes, which outnumbered small insertion and/or deletion (indel; 14%) and nonsense and splice-site (12%) modifications. It was not possible to identify chromosome rearrangements by exome sequencing; thus, the frequency of chimeric genes that was previously described 4, 5 remains to be evaluated in this data set.
The observed mutation spectrum could be indicative of specific mutagenesis mechanisms occurring in tumor cells. l e t t e r s variants, showing an over-representation of nucleotide transversion, particularly of G:C>T:A changes (Fig. 1b) . This mutation spectrum strongly differs from that usually observed in other solid tumors, where C:G>T:A transitions are the most abundant alteration 3 . Moreover, in HCC tumors, G>T transversions were significantly enriched in the non-transcribed DNA strand (Fig. 1c,d) , which is less efficiently repaired after genotoxic injury 6, 7 . We then searched for association with clinical features and found that G:C>T:A changes were significantly more frequent in HCC tumors that developed on non-cirrhotic livers (P = 0.01; Supplementary Table 4) and in welldifferentiated tumors (P = 0.01) than in other tumor types. These results strongly suggest that exposure to genotoxic agents could contribute to hepatocarcinogenesis independent of cirrhotic status. The best-characterized genotoxic inducer involved in HCC is exposure to aflatoxin B1 in combination with HBV infection in subtropical regions, which is associated with G>T transversion at codon 249 of TP53 (refs. 8,9) . However, in the present series of individuals with HCC living in France, the causative genotoxic agent remains to be determined by epidemiological and/or toxicological studies focusing on persons with non-cirrhotic HCC.
SNP array analysis of 125 HCC tumors identified frequent chromosome gains (at 1q, 5, 6p, 7, 8q, 17q and 20) and losses (at 1p, 4q, 6q, 8p, 13q, 16, 17p and 21), as previously described in HCC 10 ( Supplementary Fig. 3a) . Hyperploid DNA content (ploidy of ≥3) was found in 20% of tumors and was associated with poor tumor differentiation (Edmondson tumor grade III or IV, P = 0.03; Supplementary Table 4 ). We also evaluated the level of chromosomal instability in each tumor by calculating the fraction of aberrant arms (FAA; the proportion of chromosome arms altered on more than 40% of their length). Highly rearranged copy-number profiles were more frequent in HCC tumors that developed in non-cirrhotic liver (P = 0.04; Supplementary Table 4) or with HBV infection (P = 0.01) and in tumors with high serum α-fetoprotein (P = 0.03), large size (P = 0.004) or poor tumor differentiation (Edmondson tumor grade III or IV, P = 0.04) than in other tumor types. Focal chromosome amplifications (of <3 Mb) were identified in 32% of the tumors. We observed only one region, at 11q13.3, that was amplified in two tumors (Supplementary Table 5 ); this region included CCND1 and FGF19, two genes previously found to be amplified in HCC 11 . Homozygous deletions were more frequent (40%) and were usually focal (mean size = 0.2 Mb; Supplementary Table 6), and these deletions were significantly associated with tumor aggressiveness (Edmondson tumor grade III or IV, P = 0.04; high levels of serum α fetoprotein, P = 0.008; microscopic vascular invasion, P = 0.009; Supplementary Table 4 ) and poor survival (P < 0.0001; Supplementary Fig. 3b ). A total of 12 regions were recurrently altered by homozygous deletion; with the most frequently affected located at the CDKN2A-CDKN2B (6.4%), AXIN1 (3.2%) and IRF2 (3.2%) loci ( Supplementary Fig. 4) .
To obtain a more comprehensive understanding of the altered genetic landscape in HCC, we performed additional screening for mutations present in seven genes expressed in liver that were modified by homozygous deletion and/or mutation in at least three tumors ( Fig. 2 and Supplementary Tables 3 and 6). We also screened seven other genes well known to be recurrently altered in hepatocellular adenoma (IL6ST 12 and HNF1A 13 ) and cases of HCC (ARID2 (ref. 14) , TP53, APC, PIK3CA and KRAS 10 ). Mutational screening in 125 HCC samples identified 4 genes (CTNNB1, TP53, ARID1A and AXIN1) that were altered in more than 10% of the tumors, whereas the other genes were less frequently mutated. We identified a total of 118 somatic point mutations in 125 tumors (Supplementary Table 7 ). The spectrum of mutations showed a distribution similar to that observed in exome sequencing, with an over-representation of G>T transversions on the non-transcribed DNA strand (Fig. 1d) . Hence, we confirmed the genotoxic signature in this series of HCC tumors of various etiologies.
In both the exome sequencing and tumor validation sets (n = 125), the Wnt/β-catenin pathway was the most frequently altered, with the occurrence of either activating mutations in CTNNB1 (encoding β-catenin; 32.8%) or inactivating mutations in AXIN1 (15.2%) or APC (1.6%) ( Fig. 3 and Supplementary Table 8) . CTNNB1, AXIN1 and APC gene alterations were mutually exclusive (only one HCC tumor had mutations in both CTNNB1 and AXIN1). The mutation spectra were classical, except for four rare CTNNB1 mutations identified in exons 6 to 8 ( Supplementary Fig. 5 and Supplementary Table 7) . CTNNB1 mutations defined a homogenous subtype of HCC not related to HBV infection (P = 0.001) and associated with transcriptome subclasses G5-G6 (ref. 15) (P < 1 × 10 −9 ; Fig. 2 and Supplementary Table 4 ). In contrast, AXIN1 and APC mutations occurred in HCC of various etiologies, including tumors occurring in the presence of HBV infection. With exome sequencing, unique mutations in the FZR1, CSNK1E and CDC16 genes that are related to the Wnt/β-catenin pathway were also identified but were not further evaluated. 
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The p53 pathway was identified as the second most frequently altered pathway in HCC. This was evidenced by the presence of TP53-inactivating mutations (20.8%) and homozygous deletions or mutations in CDKN2A (8%) (Fig. 3) . TP53 alterations were mostly exclusive from CTNNB1 mutations (P = 0.0001; Supplementary Table 4) but not from AXIN1 and APC alterations. In accordance with the well-known function of p53 in the maintenance of chromosome stability, TP53 mutations were more frequent in HCC samples with a high number of chromosomal rearrangements (P = 0.003). IRF2 (encoding interferon regulatory factor 2) inactivation was also identified in 6 of 125 HCC tumors (4.8%) and was caused by homozygous deletion or splice-site or missense mutations ( Supplementary Fig. 4 and Supplementary Table 7) . The IRF2 protein, an interaction partner of the p53 inhibitor MDM2, acts as a transcriptional regulator through its DNA-binding activity and protein-protein interactions 16 . It has been reported to have a major role in cell growth regulation and immune response. Of note, both splicing and missense mutations affected the Lys137 residue, which is known to be sumoylated, thereby affecting IRF2 transcriptional activity 17 . All six tumors had biallelic alteration of IRF2 and were associated with HBV infection (P = 0.0003; Supplementary Table 4) .
IRF2 mutations were also associated with hyperploidy and high chromosomal instability (P = 0.01). We then tested the putative tumor suppressor function of IRF2 in two cell lines, HepaRG and HepG2, both of which have wild-type TP53. In our studies, small interfering RNA (siRNA)-mediated IRF2 silencing significantly increased cell proliferation ( Fig. 4a and Supplementary Fig. 6a ). In contrast, IRF2 overexpression induced substantial apoptotic cell death (Fig. 4b,c and Supplementary Fig. 6b,c) . In vivo, stable IRF2 extinction by small hairpin RNA (shRNA) in HepaRG cells resulted in increased tumor growth in a subcutaneous xenograft model in CD-1 nude mice ( Fig. 4d and Supplementary Fig. 6d ). IRF2 and TP53 mutations were mutually exclusive, whereas tumors mutated for either IRF2 or TP53 mainly belonged to the same transcriptome class G1-3 (ref. 15). Because IRF2 is known to bind to MDM2 (ref. 18) , we hypothesized that lack of IRF2 could impair p53 function. In agreement with this, we showed that IRF2 silencing decreased p53 protein levels and p53 target gene mRNA expression in HepaRG cells (Fig. 4e,f) . Moreover, a strong correlation between IRF2 and p53 protein levels was observed. Thus, our study shows for the first time the role of IRF2 as a tumor suppressor in HBV-associated HCC and its function as a regulator of the p53 pathway. Figure 3 Major pathways commonly altered by somatic mutations or homozygous gene deletions. Alteration frequencies are expressed as the percentages of mutation and/or homozygous deletion in the validation series of 125 (red, activated; blue, inactivated) or in the 24 exome-sequenced HCCs (gray); for gene mutations that were unique, no frequency is given. Positive and negative interactions are indicated.
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Genes encoding chromatin remodeling complex components constituted the third most frequently altered class identified in exome screening. In addition, we validated ARID1A and ARID2 mutations in 16.8% and 5.6% of the cases in the tumor validation set, respectively. The ARID1A and ARID2 proteins are part of the SWItch/Sucrose Non-Fermentable (SWI/SNF)-related chromatin remodeling complexes that controls the accessibility of promoter regions to the transcriptional machinery and has been shown to have tumor suppressor functions 19, 20 . ARID1A belongs to the Brg1-associated factor (BAF) complex and was recently shown to be inactivated in several tumor types, including gastric, ovarian and bladder carcinoma, but its involvement in HCC has never been reported [21] [22] [23] [24] . Here, we identified mutations predicted to inactivate ARID1A function similar to those described in other tumor types (Supplementary Fig. 5 ). ARID1A mutations were significantly more frequent in HCC related to alcohol intake (P = 0.002) than in tumors of other etiology and showed a significant association with CTNNB1 mutations (P = 0.05; Supplementary Table 4) . In contrast, mutations in ARID2, whose protein product belongs to the polybromo-and Brg1-associated factor (PBAF) complex, were less frequent but exclusive from ARID1A mutations. Overall, ARID2 mutation frequency was similar to that previously observed in HCC 14 but was not significantly associated with hepatitis C virus (HCV) infection or any other risk factor in our study. In exome sequencing, we identified mutations in additional genes participating in chromatin remodeling (PBRM1, SMARCA1, SMARCA2, SMARCA4, SMARCAB1 and SMARCD1) (Fig. 3) . However, most of these mutations were not recurrent and were not exclusive from ARID1A and ARID2 alterations. The mutation frequencies of these six genes remains to be evaluated in larger series of HCC samples, but, overall, more than 24% of HCC tumors had a mutation in at least one gene related to chromatin remodeling, thereby indicating that this pathway might significantly contribute to hepatocyte tumorigenesis.
Among the genes less frequently mutated in HCC, we identified, for the first time in solid tumors, recurrent mutations in RPS6KA3 (9.6%), a gene located on chromosome X that encodes the ribosomal S6 protein kinase 2 (RSK2). RSK2 is a serine/threonine kinase of the Ras/MAPK signaling pathway that is directly phosphorylated and activated by extracellular-regulated kinases 1 and 2 (ERK1/2). RSK2 exerts feedback inhibition on the ERK1/2 pathway by phosphorylating and inhibiting the guanine nucleotide exchange factor SOS 25, 26 . Half of the RPS6KA3 mutations we identified led to premature stop codons or altered splicing sites, whereas four out of seven missense mutations were located close to the codons for the Ser227 and Thr557 phosphorylation sites that are required for RSK2 activation (Supplementary Fig. 5 ). Consequently, RPS6KA3 somatic mutations were predicted to inactivate RSK2 function. Other components of the Ras/MAPK and phosphatidylinositol 3-kinase (PI3K) pathways were rarely mutated (Fig. 3) . Of note, in 11 tumors out of 12, RPS6KA3 mutations were found in HCC that developed in the absence of cirrhosis (P = 0.05), and alterations in 
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RPS6KA3 were frequently associated with AXIN1 mutations (P = 0.02; Supplementary Table 4) , suggesting cooperation between RPS6KA3 inactivation and Wnt/β-catenin activation in tumorigenesis. Finally, NFE2L2 was mutated in 6.4% of HCC tumors (Fig. 3) . NFE2L2 encodes NRF2, a transcription factor that is crucial for cellular redox homeostasis. All NFE2L2 mutations were located within the DLG and ETGE motifs, hotspots of somatic mutations previously identified in lung, esophageal, laryngeal and skin squamous cell carcinomas [27] [28] [29] ( Supplementary Fig. 5 ). These mutations are known to inhibit KEAP1-mediated degradation of NRF2. Of note, six out of eight HCC samples with NFE2L2 mutations also had CTNNB1 mutations (P = 0.01), with another tumor also having an AXIN1 mutation. Moreover, an additional tumor with a KEAP1-inactivating mutation was also found to have a mutation in CTNNB1. Hence, these results identify for the first time in HCC a role for alteration in the oxidative stress pathway, mainly in tumors with activated Wnt/β-catenin signaling.
In conclusion, we have identified new genes recurrently altered in HCC, which suggest a major role for SWI/SNF chromatin remodeling complexes and involvement of both interferon and oxidative stress pathways in hepatocellular malignant proliferation and transformation.
URLs. EGA, https://www.ebi.ac.uk/ega/; ICGC, http://www.icgc. org/; data from this study, ftp://data.dcc.icgc.org/version_8/; R spider, http://www.bioprofiling.de/R_spider.html; KEGG, http://www. genome.jp/kegg/; Reactome, http://www.reactome.org/; GEO, http:// www.ncbi.nlm.nih.gov/geo/.
MeTHods
Methods and any associated references are available in the online version of the paper.
Accession codes. Sequencing data have been deposited at the European Genome-phenome Archive (EGA; EGAS00001000217). Comparative genomic hybridization data have been deposited at the Gene Expression Omnibus (GEO; GSE32649). All variants and tumor features are deposited at the International Cancer Genome Consortium (ICGC) portal.
Immunohistochemistry. Tumor samples were fixed in 4% neutralbuffered formalin for 48 h, and paraffin blocks were sectioned at a thickness of 5 µm. Endogenous peroxidases and biotins were blocked with PeroxidaseBlocking Solution (Dako Real) and the Vector Avidin/Biotin Blocking Kit (Vector Laboratories), respectively. Antigen retrieval was performed in boiling citrate buffer (pH 9.5; PowerVision). Sections were blocked with goat normal serum (Vectastain) and incubated for 1 hour with an antibody to IRF2 (1:100 dilution; rabbit polyclonal, clone H-229, Santa Cruz Biotechnology), and detection was amplified using the Vectastain ABC kit (Elite).
Statistical analysis. Contingency tables, along with tests of independence and measures of association, were performed in R using the X-squared test (group size of >5) with Yates' continuity correction or Fisher's Exact test (group size of ≤5) and the Kruskal-Wallis rank-sum test (continuous variables). Variables associated with overall survival were identified using Cox proportional hazards regression models (log-rank test) with the R survival library, and only individuals with HCC with curative (R0) resection were included in survival analysis (n = 99, exclusion of non-curative resections and liver transplants). Kaplan-Meier plots were used to describe survival rates. qRT-PCR expression data were presented as mean ± s.d., and non-parametric Mann-Whitney tests were used to compare quantitative values. All reported P values were two tailed, and differences were considered significant when the P value was less than 0.05.
